News
Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.
Prasad, a longtime critic of the FDA’s leniency in drug approvals, joined the agency in May. WASHINGTON — The Food and Drug ...
The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...
Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the Food and Drug Administration after a pressure campaign from far-right ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
4h
India Today on MSNWhat forced Vinay Prasad to exit top job at US FDA in just 3 monthsIndian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the leaders in gene therapy goes through a “strategic ...
The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.
20h
TipRanks on MSNSarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy UseShares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results